

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### Survey of Pregabalin augmentation in patients with chronic post traumatic stress disorder

#### Protocol summary

##### Summary

Objective: The aim of this study was to evaluate the effectiveness of Pregabalin augmentation to antidepressant treatment (Selective Serotonin Reuptake Inhibitors and Sodium valproate) in patients with chronic posttraumatic stress disorder (PTSD). Methods: This was a double-blinded placebo-controlled clinical trial conducted at Ibn-E-Sina Hospital (Mashhad, Iran) at 2013. 37 male patients diagnosed with PTSD based on DSM-IV-TR criteria were randomly allocated to two groups. The case group (18 patients) received Pregabalin (300 mg/day) and stable doses of antidepressants and the control group (19 patients) received placebo and routine treatment for 6 weeks. Assessments were done at baseline; two, four and six weeks based on PTSD Check List-Military version (PCL-M), Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and Spitzer quality of life index. Inclusion criteria: diagnose with PTSD based on DSM-IV-TR criteria and sensitivity to Pregabalin and active medical disease were Exclusion criteria.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201302145280N12**

Registration date: **2013-08-30, 1392/06/08**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2013-08-30, 1392/06/08

##### Registrant information

###### Name

Raheleh Nejati

##### Name of organization / entity

Mashhad University of Medical Sciences, Ibn-e- Sina Psychiatric Hospital

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 3711 2540

##### Email address

nejatir2@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Mashhad University of Medical Sciences

##### Expected recruitment start date

2012-09-22, 1391/07/01

##### Expected recruitment end date

2013-09-23, 1392/07/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Survey of Pregabalin augmentation in patients with chronic post traumatic stress disorder

##### Public title

Survey of Pregabalin augmentation in patients with chronic post traumatic stress disorder

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: diagnose with PTSD based on DSM-IV-TR criteria, age between 30 and 65 years, had no significant cognitive disorder and no history of drug abuse except for nicotine. Exclusion criteria: were unwillingness of patients to continue the trial; active medical disease, other diseases in axis one or two except

for PTSD and sensitivity to Pregabalin.

#### Age

From **35 years** old to **60 years** old

#### Gender

Male

#### Phase

N/A

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **38**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

#### Blinding (investigator's opinion)

Double blinded

#### Blinding description

#### Placebo

Used

#### Assignment

Parallel

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Mashhad University of Medical Sciences

##### Street address

Ghoreish building, Daneshgah Street.

##### City

Mashhad

##### Postal code

#### Approval date

2011-11-26, 1390/09/05

#### Ethics committee reference number

900441

## Health conditions studied

### 1

#### Description of health condition studied

chronic Post-traumatic stress disorder( PTSD)

#### ICD-10 code

F43.1

#### ICD-10 code description

Post-traumatic stress disorder

## Primary outcomes

### 1

#### Description

Post traumatic stress disorder

#### Timepoint

0, 2, 4 and 6th weeks

#### Method of measurement

PCL test

## Secondary outcomes

### 1

#### Description

Quality of life

#### Timepoint

0, 2, 4 and 6th weeks

#### Method of measurement

Spitzer Quality of Life index( SQL)

### 2

#### Description

Depression

#### Timepoint

0, 2, 4 and 6th weeks

#### Method of measurement

Hamilton Depression Rating Scale

### 3

#### Description

Anxiety

#### Timepoint

0, 2, 4 and 6th weeks

#### Method of measurement

Hamilton Anxiety Rating Scale

## Intervention groups

### 1

#### Description

The case group received SSRI( Sertraline 50-200 mg or citalopram 20-40 mg) daily for 6 weeks. received Pregabalin (75 mg/day for the first week then 75 mg twice daily for the second week and continued with 150 mg twice daily from the third week to the sixth week) .

#### Category

Treatment - Drugs

### 2

#### Description

control group received placebo and routine treatment daily for 6 weeks.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Ebn-e- sina hospital

**Full name of responsible person**  
**Street address**  
**City**  
mashhad

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Ardakanian Marjan  
**Street address**  
Ghoreish building, Daneshgah street.  
**City**  
Mashhad  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Mashhad University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
*empty*  
**Domestic or foreign origin**  
*empty*  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Dr Mahdi Baniasadi  
**Position**  
MD  
**Other areas of specialty/work**  
**Street address**  
Ebn-e-sina hospital. hore ameli blv.  
**City**  
Mashhad  
**Postal code**  
**Phone**  
+98 51 1711 2721  
**Fax**  
**Email**  
mehdi.baniasadi@yahoo.com  
**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Dr Mohammad Reza Fayyazi Bordbar  
**Position**  
Associate Professor  
**Other areas of specialty/work**  
**Street address**  
Ibn-E- Sina Hospital  
**City**  
mashhad  
**Postal code**  
**Phone**  
+98 51 1711 2540  
**Fax**  
**Email**  
fayyaziMr@mums.ac.ir  
**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Dr Mahdi Bniasadi  
**Position**  
MD  
**Other areas of specialty/work**  
**Street address**  
Ebn-e-sina hospital, hore ameli blv.  
**City**  
Mashhad  
**Postal code**  
**Phone**  
+98 51 1711 2721  
**Fax**  
**Email**  
**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**  
*empty*  
**Study Protocol**  
*empty*  
**Statistical Analysis Plan**  
*empty*  
**Informed Consent Form**  
*empty*  
**Clinical Study Report**  
*empty*  
**Analytic Code**  
*empty*  
**Data Dictionary**  
*empty*